Reports Q3 revenue $32.9M, consensus $27.2M. “We’re pleased to report another quarter of strong financial results and we are now actively executing on our investment strategy as evidenced by the recent Tolerance, Ovid, Novan and Primrose transactions, in which we collectively invested over $75 million in Q3 and early Q4 2023,” said Todd Davis, CEO of Ligand. “We have a strong balance sheet and are generating positive cash flow which positions us advantageously in this market to further build a robust portfolio of assets that are expected to drive future revenue growth. We look forward to sharing our long term financial forecast at our upcoming Investor and Analyst Day scheduled for December 12th in New York City.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LGND:
- Sermonix announces case report during ELAINE-1 study of Lasofoxifene
- Ligand Pharmaceuticals Inc (LGND) Q3 Earnings Cheat Sheet
- Ligand acquires Tolerance Therapeutics for $20M in cash
- Biotech Alert: Searches spiking for these stocks today
- Ovid Therapeutics, Ligand enter $30M agreement for soticlestat